|
1
|
Tournade MF, Com-Nougué C, Voûte PA,
Lemerle J, de Kraker J, Delemarre JF, Burgers M, Habrand JL,
Moorman CG, Bürger D, et al: Results of the sixth international
society of pediatric oncology Wilms' tumor trial and study: A
risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol.
11:1014–1023. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Graf N, van Tinteren H, Bergeron C, Pein
F, van den Heuvel-Eibrink MM, Sandstedt B, Schenk JP, Godzinski J,
Oldenburger F, Furtwängler R and de Kraker J: Characteristics and
outcome of stage II and III non-anaplastic Wilms' tumour treated
according to the SIOP trial and study 93-01. Eur J Cancer.
48:3240–3248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davidoff AM, Giel DW, Jones DP, Jenkins
JJ, Krasin MJ, Hoffer FA, Williams MA and Dome JS: The feasibility
and outcome of nephron-sparing surgery for children with bilateral
Wilms' tumor. The St Jude children's research hospital experience:
1999–2006. Cancer. 112:2060–2070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akkina S and Becker BN: MicroRNAs in
kidney function and disease. Transl Res. 157:236–240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang X, Xiang G, Wang Y, Zhang L, Yang X,
Cao L, Peng H, Xue P and Chen D: MicroRNA-590-5p regulates
proliferation and invasion in human hepatocellular carcinoma cells
by targeting TGF-β RII. Mol Cells. 33:545–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao X, Tang C, Xiao S, Fu C and Yu P:
Enhancement of proliferation and invasion by MicroRNA-590-5p via
targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res.
20:537–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shan X, Miao Y, Fan R, Qian H, Chen P, Liu
H, Yan X, Li J and Zhou F: MiR-590-5P inhibits growth of HepG2
cells via decrease of S100A10 expression and inhibition of the Wnt
pathway. Int J Mol Sci. 14:8556–8569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu T, Nie F, Yang X, Wang X, Yuan Y, Lv
Z, Zhou L, Peng R, Ni D, Gu Y, et al: MicroRNA-590 is an
EMT-suppressive microRNA involved in the TGF-β signaling pathway.
Mol Med Rep. 12:7403–7411. 2015.PubMed/NCBI
|
|
10
|
Chu Y, Ouyang Y, Wang F, Zheng A, Bai L,
Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer
cell growth and invasion by targeting CHL1. J Cell Biochem.
115:847–853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tongaonkar HB, Qureshi SS, Kurkure PA,
Muckaden MA, Arora B and Yuvaraja TB: Wilms Tumor: An Update.
Indian J Urol. 23:458–466. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Menssen HD, Siehl JM and Thiel E: Wilms
tumor gene (WT1) expression as a panleukemic marker. Int J Hematol.
76:103–109. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Gao P, Lin F, Long M, Weng Y,
Ouyang Y, Liu L, Wei J, Chen X, He T, et al: Wilms' tumour
suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung
cancer through interaction with PI3K/Akt pathway. Cancer Cell
Intern. 13:1142013. View Article : Google Scholar
|
|
14
|
Tatsumi N, Oji Y, Tsuji N, Tsuda A,
Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, et
al: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing
agent for solid tumors. Int J Oncol. 32:701–711. 2008.PubMed/NCBI
|
|
15
|
Zhang J and Ma L: MicroRNA control of
epithelial-mesenchymal transition and metastasis. Cancer Metast
Rev. 31:653–662. 2012. View Article : Google Scholar
|
|
16
|
Favreau AJ and Sathyanarayana P:
miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly
regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia. Leuk
Res. 36:334–341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jalava SE, Urbanucci A, Latonen L,
Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL
and Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is
overexpressed in castration-resistant prostate cancer. Oncogene.
31:4460–4471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yifru S and Muluye D: Childhood cancer in
Gondar University Hospital, Northwest Ethiopia. BMC Res Notes.
8:4742015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ochicha O, Gwarzo AK and Gwarzo D:
Pediatric malignancies in Kano, Northern Nigeria. World J Pediatr.
8:235–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chu A, Heck JE, Ribeiro KB, Brennan P,
Boffetta P, Buffler P and Hung RJ: Wilms' tumour: A systematic
review of risk factors and meta-analysis. Paediatr Perinat
Epidemiol. 24:449–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scélo G and Brennan P: The epidemiology of
bladder and kidney cancer. Nat Clin Prac Urol. 4:205–217. 2007.
View Article : Google Scholar
|
|
22
|
Schüz J, Schmidt LS, Kogner P, Lähteenmäki
PM, Pal N, Stokland T and Schmiegelow K: Birth characteristics and
Wilms tumors in children in the Nordic countries: A register-based
case-control study. Int J Cancer. 128:2166–2173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beckwith JB, Kiviat NB and Bonadio JF:
Nephrogenic rests, nephroblastomatosis and the pathogenesis of
Wilms' tumor. Pediatr Pathol. 10:1–36. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Beckwith JB: Nephrogenic rests and the
pathogenesis of Wilms tumor: Developmental and clinical
considerations. Am J Med Genet. 79:268–273. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dallosso AR, Hancock AL, Brown KW,
Williams AC, Jackson S and Malik K: Genomic imprinting at the WT1
gene involves a novel coding transcript (AWT1) that shows
deregulation in Wilms' tumours. Hum Mol Genet. 13:405–415. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Menke AL, van der Eb AJ and Jochemsen AG:
The Wilms' tumor 1 gene: Oncogene or tumor suppressor gene? Int Rev
Cytol. 181:151–212. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Amini Nik S, Hohenstein P, Jadidizadeh A,
Van Dam K, Bastidas A, Berry RL, Patek CE, Van der Schueren B,
Cassiman JJ and Tejpar S: Upregulation of Wilms' tumor gene 1 (WT1)
in desmoid tumors. Int J Cancer. 114:202–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oji Y, Suzuki T, Nakano Y, Maruno M,
Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, et
al: Overexpression of the Wilms' tumor gene W T1 in primary
astrocytic tumors. Cancer Sci. 95:822–827. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo
T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, et al:
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T
lymphocytes by WT1 peptide vaccine and the resultant cancer
regression. Proc Natl Acad Sci USA. 101:13885–13890. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang L, Han Y, Suarez Saiz F and Minden
MD: A tumor suppressor and oncogene: The WT1 story. Leukemia.
21:868–876. 2007.PubMed/NCBI
|
|
31
|
Hohenstein P and Hastie ND: The many
facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 Spec No.
2:R196–R201. 2006. View Article : Google Scholar
|
|
32
|
Xu C, Wu C, Xia Y, Zhong Z, Liu X, Xu J,
Cui F, Chen B, Røe OD, Li A and Chen Y: WT1 promotes cell
proliferation in non-small cell lung cancer cell lines through
up-regulating cyclin D1 and p-pRb in vitro and in vivo. PLoS One.
8:e688372013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Algar EM, Khromykh T, Smith SI, Blackburn
DM, Bryson GJ and Smith PJ: A WT1 antisense oligonucleotide
inhibits proliferation and induces apoptosis in myeloid leukaemia
cell lines. Oncogene. 12:1005–1014. 1996.PubMed/NCBI
|
|
34
|
Davies JA, Ladomery M, Hohenstein P,
Michael L, Shafe A, Spraggon L and Hastie N: Development of an
siRNA-based method for repressing specific genes in renal organ
culture and its use to show that the Wt1 tumour suppressor is
required for nephron differentiation. Hum Mol Genet. 13:235–246.
2004. View Article : Google Scholar : PubMed/NCBI
|
